Neurotech clears secondary trading for new share issue

The latest announcement is out from Neurotech International ( (AU:NTI) ).

Neurotech International has issued new fully paid ordinary shares without a prospectus under the Corporations Act’s secondary trading provisions, confirming the securities were detailed in an Appendix 2A lodged on 30 March 2026. The company states it is fully compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information that investors would reasonably expect in a disclosure document, supporting secondary trading of the newly issued shares.

The announcement reinforces Neurotech’s regulatory standing and transparency obligations at a time when its clinical programs for NTI164 in paediatric neurological conditions are advancing. This may provide additional comfort to existing and prospective shareholders regarding the tradability of the new securities and the company’s adherence to market disclosure standards as it progresses towards later-stage clinical milestones.

The most recent analyst rating on (AU:NTI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.

More about Neurotech International

Neurotech International is a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, developing its lead oral broad-spectrum cannabinoid drug candidate NTI164. The company has reported clinically meaningful, statistically significant results with a favourable safety profile across Phase I/II and Phase II/III trials in Autism Spectrum Disorder, PANDAS/PANS and Rett Syndrome, and has ethics clearance for a Phase III ASD trial.

Average Trading Volume: 1,298,330

Technical Sentiment Signal: Sell

Current Market Cap: A$16.85M

See more insights into NTI stock on TipRanks’ Stock Analysis page.